NCT03216343View on ClinicalTrials.gov

Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 9, 2017

Primary Completion Date

November 4, 2022

Study Completion Date

May 15, 2023

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Chiauranib

CS2164

Trial Locations (1)

Unknown

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Chipscreen Biosciences, Ltd.

INDUSTRY

NCT03216343 - Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter